SEC Filing Summary: Amedica Corporation (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Amedica Corporation on August 12, 2014, reporting events occurring on August 11, 2014. The filing details the issuance of an additional senior unsecured convertible note to MG Partners II Ltd., an affiliate of Magna, following a prior agreement disclosed on July 1, 2014.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company issued an Additional Convertible Note with an original principal amount of $3.5 million for a fixed purchase price of $3.5 million.
- Total Debt Obligation: Combined with the Initial Convertible Note ($2.9 million principal), the total principal amount of the Convertible Notes is $6.4 million.
- Interest Rate: The notes accrue interest at an annual rate of 6.0%.
- Maturity Date: June 30, 2016 (subject to extension).
- Conversion Terms: Convertible at the Investor's option into Common Stock at an initial fixed price of $3.75 per share.
- Liquidity Impact: The transaction provided immediate cash proceeds of $3.5 million from the Additional Convertible Note.
Material Changes and Conditions
The filing discloses specific conditions triggered by the Company's stock price performance. Because the closing sale price of the Common Stock fell below 110% of the Initial Fixed Price ($3.75) for two consecutive trading days, the following provisions apply:
- Redemption Option: The Company has 60 days to redeem the notes in full at a 127.5% premium of the principal and accrued interest.
- Conversion Price Adjustment: On the 61st day, the Investor may convert at the lesser of the Initial Fixed Price or 80% of the lowest daily volume weighted average price (VWAP) over the five trading days prior to conversion.
- Default Provisions: In the event of default, the interest rate increases to 18%, and the redemption price is calculated at a premium (135% or 127.5% depending on the scenario).
Outlook, Risks, and Restrictions
The filing outlines significant restrictions on the Investor to manage market impact and short-selling risks:
- Short Sale Prohibition: The Investor is prohibited from engaging in short sale transactions while the notes are outstanding.
- Sale Restrictions: Upon conversion, the Investor cannot sell more than the greater of $125,000 or 15% of daily trading volume in any five consecutive trading days. This limit increases to 33% of daily volume if trading exceeds $250,000.
- Restriction Removal: Investor restrictions are removed if the stock price trades below $2.50.
- Prepayment: The Company retains the right to prepay the notes in whole or in part at 127.5% of the outstanding principal.
Investor Verification Checklist
- Verify the current market price of Amedica Corporation's Common Stock relative to the $3.75 conversion price and the $2.50 restriction threshold.
- Confirm the Company's cash position to assess its ability to meet the 127.5% redemption premium if the 60-day window expires.
- Review the Company's liquidity status to ensure it can service the 6.0% interest and potential 18% default interest.
- Monitor the 60-day countdown period for the redemption option triggered by the stock price decline.
- Check for any subsequent filings regarding the exercise of the conversion option or prepayment of the notes.